… Little is still known about its real-world effectiveness and safety in the italian population. Aim
… and safety of dabigatran in a large single-center cohort of “real-life” italian population with …

… Therefore, we compared the effectiveness and safety of dabigatran with warfarin in clinical
… and safety >2 years after dabigatran became available and among patient demographic …

… The aim of this study was to assess the efficacy and safety in an “everyday clinical practice”
population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran …

… to assess the effectiveness and safety of dabigatran (direct thrombin inhibitor) vs.
acenocoumarol (vitamin K antagonist) in patients with atrial fibrillation (AF) in daily clinical practice. …

… In the RE-LY trial, dabigatran 150 mg twice daily was … dabigatran 110 mg twice daily was
noninferior. Both doses greatly reduced hemorrhagic stroke, and dabigatran 110 mg twice daily …

… In the RE-LY clinical trial, dabigatran presented a better effectiveness/ safety profile when …
of the real-world setting. We aimed to assess the performance of dabigatran in real-world …

… 1-year real-life risk of major clinical events with dabigatran or rivaroxaban versus … real-life
effect of dabigatran and rivaroxaban compared with VKAs, as used in the general population. …

… in daily care. To evaluate treatment persistence, effectiveness and safety of dabigatran therapy
in SPAF patients in daily … on novel oral anticoagulants in daily care. Between October 1, …

… the safety and efficacy of dabigatran relative to warfarin for stroke prevention in non-valvular
atrial fibrillation. It is important to further evaluate safety … to compare dabigatran with warfarin …

… global registry designed to characterize the population of newly diagnosed patients with …
world. GLORIA-AF we will be able to evaluate the real performance at world level of dabigatran …